MurrayCJ, LopezAD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet, 1997; 349:1498–1504.
2.
JoshiM, JoshiA, BartterT: Symptom burden in chronic obstructive pulmonary disease and cancer. Curr Opin Pulm Med, 2012; 18:97–103.
3.
ChinC, BoothS: Managing breathlessness: A palliative care approach. Postgrad Med J, 2016; 92:393–400.
4.
AntoniuSA: Descriptors of dyspnea in obstructive lung diseases. Multidiscip Respir Med, 2010; 5:216.
5.
AbernethyAP, WheelerJL: Total dyspnoea. Curr Opin Support Palliat Care, 2008; 2:110–113.
6.
MularskiRA, ReinkeLF, Carrieri-KohlmanV, et al.: An official American Thoracic Society workshop report: Assessment and palliative management of dyspnea crisis. Ann Am Thorac Soc, 2013; 10:S98–S106.
7.
RoglianiP, CalzettaL, CoppolaA, et al.: Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med, 2017; 124:6–14.
8.
MarciniukDD, GoodridgeD, HernandezP, et al.: Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: A Canadian Thoracic Society clinical practice guideline. Can Respir J, 2011; 18:69–78.
NaderiN, AssayagD, Mostafavi-Pour-ManshadiS-M-Y, et al.: Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. Respir Med, 2018; 138:129–136.
11.
O'DonnellDE, AaronS, BourbeauJ, et al.: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update. Can Respir J, 2007; 14(Suppl B):5B–32B.
12.
SethiS, MartinezFJ, RabeKF, et al.: Effect of roflumilast on cough and sputum in patients with severe or very severe chronic obstructive pulmonary disease (COPD) receiving inhaled combination therapy: Evaluation of the EXAcerbation of chronic pulmonary disease tool-patient reported outcomes (EXACT-PRO) subdomain scores. A33 Clin Stud Obstr Lung Dis, 2017:A1335.
